{"id":"W4410802810","doi":"10.1200/jco.2025.43.16_suppl.10001","title":"A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) report.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Chemoimmunotherapy; Cog; Eflornithine; Neuroblastoma; Refractory (planetary science); Oncology; Internal medicine; Lomustine; Randomized controlled trial; Chemotherapy; Vincristine; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001998527,0.001716659,0.002022325,0.0004837103,0.0003548355,0.0008436321,0.001145051,0.001715865,0.006164155],"category_scores_gemma":[0.001324718,0.0007516569,0.001269025,0.0004792993,0.0009892615,0.0008958247,0.0004016016,0.002761877,0.0008873211],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001372652,"about_ca_system_score_gemma":0.001856918,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002344945,"about_ca_topic_score_gemma":0.006033659,"domain_scores_codex":[0.9994242,0.0003220865,0.0000267866,0.00008912217,0.00004002314,0.00009772952],"domain_scores_gemma":[0.9991079,0.0002100121,0.0001671599,0.00006964633,0.00005066371,0.0003946953],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.946227,0.02114747,0.001418781,0.0004305106,0.000819975,0.00008512667,0.00008049062,0.0004527213,0.006811092,0.0001366552,0.001970019,0.02042018],"study_design_scores_gemma":[0.9141528,0.08147443,0.002186384,0.00002198067,0.000268554,0.0000520302,0.00001570052,0.0002445515,0.0004034671,0.00008390784,0.00108433,0.00001197315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816394,0.003477169,0.0005962082,0.001160155,0.0004787651,0.007393835,0.002634762,0.0001179956,0.002501817],"genre_scores_gemma":[0.9669372,0.004418738,0.003574073,0.002716077,0.0005101704,0.01071019,0.004259169,0.00006981744,0.006804546],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006164155,"threshold_uncertainty_score":0.02062118,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07020402218120037,"score_gpt":0.4922415114919991,"score_spread":0.4220374893107987,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}